Welcome to our dedicated page for Neurocrine Biosciences SEC filings (Ticker: NBIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neurocrine Biosciences Inc (Nasdaq: NBIX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware-incorporated, publicly traded biopharmaceutical company, Neurocrine Biosciences reports its financial performance, material events and key corporate developments through forms such as 10-K annual reports, 10-Q quarterly reports and 8-K current reports.
In its recent Form 8-K filings, Neurocrine Biosciences has reported quarterly financial results, including net product sales for INGREZZA and CRENESSITY, research and development and selling, general and administrative expenses, and net income. These filings often incorporate press releases that discuss revenue trends, non-GAAP financial measures, R&D investment in programs such as osavampator and direclidine, and updates on collaborations. Other 8-K items may cover executive and board-related matters, such as amendments to employment agreements and changes in key leadership roles.
On this page, investors can review the full text of Neurocrine Biosciences’ periodic reports to understand how the company describes its business, risk factors, product portfolio and pipeline. The annual Form 10-K typically includes detailed sections on therapeutic focus areas like tardive dyskinesia, Huntington’s disease chorea, classic congenital adrenal hyperplasia, endometriosis and uterine fibroids, as well as discussion of the company’s neuroscience and endocrinology research strategy. Quarterly Form 10-Q filings update these disclosures and provide interim financial statements.
Stock Titan enhances these documents with AI-powered summaries that highlight the most important points from lengthy filings, helping readers quickly identify changes in revenue composition, R&D spending, collaboration milestones and other material items. Users can also monitor real-time 8-K updates for new clinical data announcements, financing activities or governance changes, and access Form 4 insider transaction reports to see how company insiders are trading NBIX shares, when such filings are available.
Whether you are evaluating Neurocrine Biosciences’ exposure to specific therapeutic areas, following its investment in late-stage programs like osavampator and direclidine, or comparing GAAP and non-GAAP results, this filings page offers a structured view of the company’s official SEC record with tools that make complex disclosures easier to interpret.
Neurocrine Biosciences Chief Scientific Officer Jude Onyia reported routine equity compensation activity. On January 31, 2026, 238 restricted stock units converted into 238 shares of common stock at an exercise price of
On the same date, 142 of those shares were withheld by Neurocrine Biosciences at
JPMorgan Chase & Co. has filed a Schedule 13G reporting a passive ownership stake in Neurocrine Biosciences, Inc. common stock. As of 12/31/2025, JPMorgan reports beneficial ownership of 5,198,084 shares, representing 5.2% of Neurocrine’s common stock.
The filing shows JPMorgan has sole voting power over 4,705,046 shares and shared voting power over 21,535 shares. It has sole dispositive power over 5,196,778 shares and shared dispositive power over 1,221 shares. JPMorgan is identified as a Delaware holding company with several subsidiaries, including J.P. Morgan Securities LLC and JPMorgan Chase Bank, National Association.
JPMorgan certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Neurocrine Biosciences.
Neurocrine Biosciences' Chief Executive Officer Kyle Gano reported option exercises and related stock sales. On January 16, 2026, he exercised non-qualified stock options and incentive stock options to acquire 34,588 and 1,812 shares of common stock, respectively, at an exercise price of $35.99 per share. On the same date, he sold 34,588 shares at a weighted average price of $132.7044 per share and 1,812 shares at a weighted average price of $132.7143 per share under a pre-established Rule 10b5-1 trading plan adopted on May 20, 2025. After these transactions, he directly owned 140,407 shares of Neurocrine Biosciences common stock. The exercised options were granted on February 5, 2016 and were scheduled to expire on February 5, 2026.
Neurocrine Biosciences Chief Commercial Officer filed an amended Form 4 to correct a previously misreported stock option exercise. On November 28, 2025, the insider exercised 12,830 incentive stock options, rather than the 5,970 options originally reported. The options had an exercise price of $35.99 per share and converted into an equal number of common shares. The filing also updates the insider’s reported beneficial ownership of Neurocrine Biosciences common stock and notes that this total includes 204 shares acquired through the company’s 2018 Employee Stock Purchase Plan. The incentive stock option was granted on February 5, 2016, vested in 48 equal monthly installments beginning March 5, 2016, and was scheduled to expire on February 5, 2026.
A holder of NBIX common stock has filed a notice of proposed sale under Rule 144, covering 36,400 common shares with an aggregate market value of $4,853,940. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an approximate sale date of 01/16/2026. Common shares outstanding were 99,705,698 as of this notice.
The 36,400 shares were acquired on 01/16/2026 by exercising stock options granted by the issuer and paid for in cash. In the past three months, the seller listed as Kyle Gano previously sold 300 common shares on 11/04/2025 for gross proceeds of $42,591. By signing the notice, the seller represents that they do not know of any undisclosed material adverse information about the issuer’s operations.
Neurocrine Biosciences Chief Legal Officer Darin Lippoldt exercised stock options for 3,349 shares of common stock on January 8, 2026. The options had an exercise price of $35.99 per share and were originally granted on February 5, 2016, vesting monthly over four years and scheduled to expire on February 5, 2026.
Following the option exercise, Lippoldt directly held 46,754 shares of Neurocrine Biosciences common stock, and the reported incentive stock option position was reduced to zero.
A director of Neurocrine Biosciences, Inc. reported stock transactions in mid-December 2025. On December 15, 2025, the director exercised 8,276 stock options at
Neurocrine Biosciences Chief Scientific Officer reports RSU vesting and tax withholding shares
The Chief Scientific Officer of Neurocrine Biosciences, Inc. reported routine equity activity on November 29, 2025. A restricted stock unit (RSU) award converted into 4,426 shares of common stock at an exercise price of $0, increasing the executive’s directly held position to 18,129 shares before tax withholding. To cover tax obligations on the RSU vesting, the company withheld 2,248 shares at a value of $152.16 per share, leaving the executive with 15,881 shares of common stock held directly after the transactions.
The RSU was originally granted on November 29, 2021 and vested in four annual tranches: 4,425 shares on November 29, 2022, 4,425 shares on November 29, 2023, 4,426 shares on November 29, 2024, and 4,426 shares on November 29, 2025, in each case subject to the award’s terms and conditions.
Neurocrine Biosciences (NBIX) reported an insider equity transaction by a director. On 11/25/2025, the reporting person exercised a non-qualified stock option for 15,000 shares of common stock at an exercise price of
On the same date, the director disposed of 15,000 shares of common stock in an open-market sale coded "S," at a weighted average price of
Neurocrine Biosciences, Inc. (NBIX) reported an update to its senior leadership arrangements. Former Chief Medical Officer Eiry W. Roberts, M.D., who transitioned to the role of Strategic Advisor effective June 2, 2025, will continue in that advisory role for an additional 12 months. On November 21, 2025, the company and Dr. Roberts entered into an amendment to her amended and restated employment agreement to extend her employment term through December 31, 2026.
The amendment is filed as an exhibit to this report, reflecting the company’s decision to retain Dr. Roberts’ expertise in a strategic advisory capacity following the appointment of Sanjay Keswani, M.D. as Chief Medical Officer.